Insulet Corporation · NASDAQ:PODD
Insulet — Investor Presentation (August 2024)
21 slides from Insulet's investor presentation, Aug 28, 2024
Slide 1: Insulet Corporation Investor Presentation
Morgan Kimsue Podder Podder since 2019 since 2023 Insulet Corporation Investor Presentation August 28, 2024
Slide 2: Forward Looking Statement; Non-GAAP Financial Measures
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Driving Continued Growth and Success
Driving Continued Growth and Success Eloise Podder since 2023 1 Drive financial results through strong execution and margin expansion Mattie Podder since 2010 2 Expand Omnipod 5’s platform for continued long- term growth 3 Delivering strong clinical outcomes with Omnipod 5 4 Innovation at the core:
Slide 4: Insulet Abbreviations and Acronyms
Insulet Abbreviations and Acronyms Business specific ADA American Diabetes Association RA Receptor Agonist AID Automated Insulin Delivery SOC Sensor of Choice bps Basis Points T1D Type 1 Diabetes CAGR Compounded Annual Growth Rate T2D Type 2 Diabetes MDI Multiple Daily Injections TAM Total Addressab
Slide 5: Achieving Our Mission with Market-Leading Innovation
Achieving Our Mission with Market-Leading Innovation Our Mission is to improve the lives of people with diabetes and enable our customers to enjoy simplicity, Shepherd & Emmett freedom, and healthier lives through Market-Leading Podders since 2023 Technology innovative technology Market-Leading Omni
Slide 6: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Revenue Gross Profit & Margin (adjusted)1 Operating Income & Margin (adjusted) 1 $s in Billions $s in Billions $s in Millions $2.5 $1.6 $300 14.0% +390 bps +720 bps 22% CAGR Expansion 69.0% $2.0 $1.4 Expansion $250 $2.0 67.7% $1.7 $1.2 12.3% $200 $1.5 $
Slide 7: Delivering Results while Expanding Our Portfolio
Delivering Results while Expanding Our Portfolio 2023 Q2’241 Q2’24 ~425,000 2 8th Total estimated active global customer base 27%3 90 bps3 U.S. Revenue growth Consecutive year of Gross Margin expansion 20% or more ~250,0002 24% 1,3 Total Company Revenue growth1 Using Omnipod 5 International Revenue
Slide 8: Expanding Omnipod 5 Platform
Expanding Omnipod 5 Platform Full Market Releases: Integration with Abbott's FreeStyle Libre 2 Plus • U.S. launch of Omnipod 5 for people with Type 2 diabetes sensor in the U.K. and Netherlands; first to (510(k) clearance received August 26, 2024) provide SOC • Integration with Dexcom’s G7 sensor in
Slide 9: Well Positioned for the Massive Market Opportunity
Well Positioned for the Massive Market Opportunity ~64M ~11M+ 3M+ ~14M+ Requiring Insulin Addressable U.S. Basal NEW Total Worldwide1 Market2 Opportunity Addressable In the markets we serve, Market ~5M type 1 and ~6M type 2 patients require insulin- intensive therapy 1. Source: IDF Diabetes Atlas 10
Slide 10: Omnipod 5 Delivers Strong Clinical Outcomes in T1D Users
Omnipod 5 Delivers Strong Clinical Outcomes in T1D Users Pod show n without Age group Time below Time in closed ne cessary adhe sive. Time in range Omnipod 5 show n without sensor range (<70) loop Strong 14-70 yrs1 73.9% 1.1% 96.7% performance in the pivotal 6-13 yrs1 68.0% 1.5% 96.4% trials 2-5 yrs
Slide 11: Winning on All Dimensions with Omnipod 5
Winning on All Dimensions with Omnipod 5 Omnipod Platform + Omnipod 5 with AID = No needles or tubes Cutting-edge algorithm using micro-dose technology Discreet, wearable, disposable Strong clinical results for MDI users 1 71% time in range and <1% time below Pay-as-you-go economics for range at low
Slide 12: Omnipod 5 Simplifies Diabetes Management
Omnipod 5 Simplifies Diabetes Management Outcomes enabled by simplicity Driving World-Class Data & Outcomes User Experience Connectivity AID Tubeless, phone-controlled, Always cloud simple interface connected Pipeline Advanced Performance with Simplicity Widespread access, seamless experience De xco
Slide 13: Solutions for a Full Range of Type 2 Needs
Solutions for a Full Range of Type 2 Needs As needs … or Omnipod 5 progress, people that to better manage disease need insulin move to Omnipod DASH ... Basal + Bolus Insulin Needs Basal The overall Omnipod experience is being continuously enhanced with new initiatives and by optimizing/automating on
Slide 14: SECURE-T2D Trial Demonstrated Striking Clinical Results with Omnipod 5 in Type 2 Diabetes
SECURE-T2D Trial Demonstrated Striking Clinical Results with Omnipod 5 in Type 2 Diabetes Pivotal trial of Omnipod 5 in 305 participants with T2D, 46% black or Hispanic, 73% on MDI, 55% on GLP-1RA1 -0.8% 2 A1C improved across subgroups: Additional clinical benefits: 11 • Black, White, and Hispanic •
Slide 15: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth • Expand the Omnipod 5 platform Drive Omnipod 5 • Additional sensor integrations Growth • Entering new international markets Expand Total • Innovate and expand product indications and global presence • Omnipod 5 for T2D clearance Addressable Market • Data product
Slide 16: Insulet Sustainability
Insulet Sustainability INNOVATING TO IMPROVE LIVES AND PRESERVE OUR PLANET Sustainability Strategic Pillars Recognition1,2 ESG Ratings Sustainable Resilient Operations Product Innovation People and Communities ESG Rankings 802kW 5.9 million pods 67% Increased renewable energy Accepted through global
Slide 17: Driving Continued Growth and Success
Driving Continued Growth and Success Temi 1 Drive financial results through strong execution and margin expansion Podder since 2021 2 Expand Omnipod 5’s platform for continued long- term growth 3 Delivering strong clinical outcomes with Omnipod 5 Holly Podder since 2017 4 Innovation at the core: dri
Slide 18: Thank You
Christian Podder since 2020 Thank Thank You You
Slide 19: Appendix
Appendix Insulet
Slide 20: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Quarter Ended June 30, Revenue 2024 2023 Percent Change Currency Impact Constant Currency U.S. Omnipod $352.3 $276.8 27.3% -% 27.3% International Omnipod 128.1 103.7 23.5% (0.9)% 24.4% Total Omnipod 480.4 380.5 26.3% (0.2)% 26.5% Drug Delivery 8.1 16.0 (49.4)% -%
Slide 21: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures FY 2023 % of FY 2022 % of FY 2020 % of Revenue Revenue Revenue Gross Profit $ 1,159.9 68.3% $ 805.6 61.7% 582.3 64.4% Voluntary MDCs1 (11.5) 57.9 — Adjusted Gross Profit $ 1,148.4 67.7% $ 863.5 66.2% $ 582.3 64.4% Operating Income $ 220.0 13.0% $ 37.6 2.9% $ 51.5